Nelkarmi FDA Approval: What GSK's Second Nuvalent Lung
Quick Facts
Why do targeted therapies matter in lung cancer?
Lung cancer remains the leading cause of cancer death worldwide, according to the World Health Organization. A meaningful subset of non-small cell lung cancer (NSCLC) is driven by specific genetic alterations, such as changes involving the ALK, ROS1, EGFR or other genes. Testing tumor tissue for these alterations, known as biomarker or molecular testing, allows clinicians to match patients to drugs that block the abnormal protein fueling the cancer.
Over the past decade, oral kinase inhibitors have changed the outlook for many of these patients, often producing longer disease control than chemotherapy alone. A recurring challenge, however, is acquired resistance: tumors develop new mutations that let them evade a drug, and brain metastases can limit options. Next-generation inhibitors are designed to address these problems.
What does the Nelkarmi approval signal?
Fierce Pharma reports that Nelkarmi is the second lung cancer drug GSK has brought to approval from its Nuvalent agreement. Nuvalent's research has centered on kinase inhibitors for oncogene-driven lung cancers, with an emphasis on activity against resistance mutations and on reaching the brain. Readers should consult the FDA label for the exact indication, the patient population and the data supporting approval.
For patients, the practical message is the importance of comprehensive biomarker testing at diagnosis and at progression. A newly approved therapy only helps if the tumor's genetic profile is known. Side effects of kinase inhibitors can include liver enzyme changes, swelling, fatigue and gastrointestinal symptoms, and treatment decisions should be made with an oncologist who can weigh benefit, safety and prior therapy history.
Frequently Asked Questions
Eligibility depends on the FDA-approved indication, typically tied to a specific genetic alteration found on tumor testing and prior treatment history. An oncologist can confirm whether a patient qualifies.
Testing identifies genetic drivers of the tumor so patients can receive matched targeted therapy, which may offer better disease control than chemotherapy for some people.
The FDA-approved prescribing information lists the official indication, dosing and safety warnings; discuss it with your care team.
References
- Fierce Pharma. GSK scores FDA approval for Nelkarmi, its 2nd lung cancer drug from Nuvalent deal. November 2026.
- World Health Organization. Lung cancer fact sheet.